secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001815776-24-000069
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025
--------------------------------------------------------------------------------

- Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.
- Cash, equivalents and marketable securities $217.2M as of Sept 30, 2024; cash runway to post-launch positive operating cash flow.
- FDA accepted NDA for LNZ100 (aceclidine) for presbyopia; PDUFA target action date Aug 8, 2025.
- Positive topline Phase 3 data from China: 74% of patients achieved 3-line or greater improvement at 3 hours (p<0.0001).
- Completed $30M private placement with Ridgeback Capital in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/0001815776-24-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/lenz-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer